Evidence map›Paper›PMID 36601262›Full record

ArticleThe World Allergy Organization journal2023

Substance P promotes immunotherapy efficacy for airway allergy.

Yongjin Wu, Yu Liu, Xinxin Wang, Huazhen Liu, Gaohui Wu, Liteng Yang, Li Guan, Qinmiao Huang, Xianhai Zeng, Pingchang Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yongjin WuDepartment of Allergy, Longgang ENT Hospital, Shenzhen Key Laboratory of ENT & Shenzhen ENT Institute, Shenzhen, China.
Yu LiuDepartments of Respirology and Allergy, Third Affiliated Hospital, Shenzhen University, Shenzhen, China.
Xinxin WangGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Shenzhen, China.
Huazhen LiuGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Shenzhen, China.
Gaohui WuDepartments of Respirology and Allergy, Third Affiliated Hospital, Shenzhen University, Shenzhen, China.
Liteng YangDepartments of Respirology and Allergy, Third Affiliated Hospital, Shenzhen University, Shenzhen, China.
Li GuanDepartments of Respirology and Allergy, Third Affiliated Hospital, Shenzhen University, Shenzhen, China.
Qinmiao HuangDepartments of Respirology and Allergy, Third Affiliated Hospital, Shenzhen University, Shenzhen, China.
Xianhai ZengDepartment of Allergy, Longgang ENT Hospital, Shenzhen Key Laboratory of ENT & Shenzhen ENT Institute, Shenzhen, China.
Pingchang YangGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, Shenzhen, China.
Shenzhen University · CNLonggang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allergen-specific immunotherapy (AIT) has been employed in the treatment of allergic diseases for many years. However, the effectiveness of AIT requires improvement. Substance P (SP) can interact with immune cells, modulate immune cell activity, and regulate immune reaction. The purpose of this study is to use SP as an immune regulator to enhance the therapeutic efficacy of AIT. Methods: An established mouse model of the airway allergy disorder (AAD) was employed with ovalbumin as a specific antigen. The AAD response was evaluated through established procedures. AAD mice were treated with AIT employing SP as an immune regulator. Dendritic cells were isolated from the airway tissues by magnetic cell sorting, and were analyzed by RNA sequencing (RNAseq). Results: We observed that after sensitization with ovalbumin, mice exhibited AAD-like symptoms, serum specific IgE, and Th2 polarization. The presence of SP in the course of sensitization prevented the development of AAD. Treating mice with SP by nasal instillations induced IL-10, but not TGF-β, in dendritic cells of the airway tissues. The most differentially expressed genes (DEG) in the dendritic cells were those related to the IL-10 expression, including Conclusion: Acting as an immune regulator, SP promotes the therapeutic efficacy for AAD by inducing antigen specific Tr1 cells in the airway tissues.

Indexed as

Airway allergy disorderAIt, allergen-specific immunotherapyDEG, Differentially expressed geneDendritic cellsImmunotherapyInterleukin-10SemaphorinSP, Substance PTr1 cell, Type 1 regulatory T cell

Identifiers

PMID36601262
PMCPMC9791926
OpenAlexW4311765330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.